Legal news - Health and pharma

DELCADE advises Geistlich Pharma AG on the majority acquisition of OST Développement — partners Maïté Lavrilleux-Carboni and Brice Wartel
Read +
Corporate lawEmployment lawFirm newsHealth and pharmaInternational law

DELCADE advises Geistlich Pharma AG on taking control of OST Développement

The European regenerative medicine market continues to consolidate. On 24 April 2026, the Swiss group Geistlich Pharma AG completed the acquisition of a majority stake in OST Développement, a French specialist in bone regeneration. DELCADE acted as legal counsel to the acquirer, extending a collaboration that began back in 2024. A two-stage M&A move The […]

  • By Brice Wartel and Maïté Lavrilleux-Carboni
  • On May 28, 2026
Read